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Purpose: Glucosamine and chondroitin are dietary supplements fre-
quently utilised by people with chronic joint pain. Evidence for symp-
tomatic or structural beneﬁt is inconclusive.
Methods: A double-blind randomised placebo-controlled clinical trial.
A total of 605 people aged 45 to 75 years with chronic knee pain and
medial tibio-femoral compartment narrowing were randomised to take
once daily: glucosamine sulfate potassium chloride1500 mg (n ¼ 152),
low molecular weight bovine-derived chondroitin sulfate 800 mg (n ¼
151), both dietary supplements (n ¼ 151) or matching placebo capsules
(n¼ 151) for two years. The primary hypotheses were that these dietary
supplements would result in reduced joint space narrowing at two
years and reduced knee pain over one year, compared to placebo. Joint
space width wasmeasured from digitised radiographs. Knee pain (0-10)
was reported daily in a Participant Diary for seven days every two
months.
Results: The mean (sd) age and BMI of this study sample was 60.5 (8.1)
years and 29.0 (5.5). At baseline, the mean (sd) medial joint space width
was 3.8 (1.0) mm and knee pain 4.7 (2.4); most evaluated knees (52%)
had early radiographic disease (Kellgren and Lawrence grade <2). Two-
year fol1ow-up in each of the allocation groups ranged from 81-85%. At
two years, mean (sd) medial joint space narrowing in the placebo group
was 0.22 (0.33) mm. After adjusting for gender, BMI, structural disease
severity and Heberdens nodes, allocation to the glucosamine-chon-
droitin combination resulted in a signiﬁcantly reduced two year joint
space narrowing compared to placebo [mean difference 0.10 mm (95%
conﬁdence interval: 0.002 to 0.20 mm); no signiﬁcant structural effect
for the single treatment allocations was detected. All allocation groups
demonstrated reduced knee pain over the ﬁrst year, with no signiﬁcant
between-group differences (p ¼ 093). However, our study appeared to
demonstrate a trend for a slightly greater knee pain reduction for the
active treatment allocations during the second year, compared to pla-
cebo. There were no signiﬁcant effects demonstrated for any of the
secondary outcome measures. Only 34 (6%) participants withdrew from
study treatment due to adverse medical events; these events were
balanced between the allocation groups.
Conclusion: The combination of glucosamine sulfate with chon-
droitin sulfate for two years resulted in a signiﬁcantly reduced joint
space narrowing among these study participants with mostly mild
structural disease severity. While all allocation groups demonstrated
reduced knee pain over the study period, none of the treatment
allocation groups demonstrated signiﬁcant symptomatic beneﬁt
above placebo.
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF BIOMECHANICAL
AND CLINICAL EFFECTS OF VALGUS KNEE BRACING
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Purpose: Clinical practice guidelines include knee braces designed to
redistribute loads across the knee, decrease pain and improve function
for patients with lower limbmalalignment and knee osteoarthritis (OA).
Despite reviewing the same literature, some guidelines support the use
of valgus knee bracing as an appropriate treatment for medial knee OA,
while others suggest inconclusive evidence to support brace use. The
objective of this systematic review andmeta-analysis was to investigate
the biomechanical effects, patient-reported outcomes, complications
and compliance with valgus brace use for medial compartment
knee OA.
Methods: Adhering to the PRISMA guidelines for systematic reviews,
ﬁve electronic databases were searched from their inception toFebruary 2013. Two reviewers independently determined study eligi-
bility, rated study quality and extracted data. Articles were ﬁrst cate-
gorized as being primarily biomechanical or clinical. We deﬁned
biomechanical articles as laboratory studies that repeated tests with
and without wearing a valgus brace. Clinical studies were further
categorized by study design including observational cohorts and
randomized clinical trials. Pooled estimates for each meta-analysis
were obtained using a random effects model. Heterogeneity was tested
using I2. For biomechanical outcome measures, standardized mean
differences (SMD) and 95% conﬁdence intervals (95%CI) were calculated
for paired samples using within-patient pre-intervention and post-
intervention means and standard deviations. For patient-reported
outcome measures in high quality randomized trials that compared a
valgus knee brace treatment group to a control group, SMD and 95%CI
were calculated using post-intervention means, standard deviations
and/or effect sizes.
Results: Thirty-eight studies were included (n ¼ 1098). Data from 16
studies were pooled in meta-analyses. Biomechanical studies suggested
a moderate, signiﬁcant decrease in the external knee adduction
moment (SMD¼0.61; 95%CI: 0.39, 0.83; p < 0.001; I2¼40.8, p ¼ 0.06)
(Figure 1) and knee adduction angular impulse during walking
(SMD¼0.77; 95%CI: 0.32, 1.23; p < 0.001; I2¼56.3, p ¼ 0.08). Random-
ized clinical trials suggested moderate, signiﬁcant improvements in
pain (SMD¼0.46; 95%CI: 0.09, 0.83; p ¼ 0.014; I2¼35.5, p ¼ 0.21) and
function (SMD¼0.39; 95%CI: 0.10, 0.68; p ¼ 0.008; I2¼0.0, p ¼ 0.44).
Studies that reported brace parameters inﬂuencing dosage were
inconsistent and unclear. No studies evaluated structural measures of
disease progression or cost of bracing. Signiﬁcant heterogeneity pre-
vented pooling of complications data. Complications reported during
brace use were slipping, discomfort and poor ﬁt, mechanical brace
problems, heat, heaviness, skin irritation, blisters and swelling. Patient-
reported brace use varied considerably between studies, but con-
sistently decreased over time.
Conclusions: This systematic review and meta-analysis of the pub-
lished literature is the ﬁrst to quantify effect sizes for valgus knee
braces. Results on biomechanical effects and clinical outcomes supports
the use of valgus knee braces in the management of medial knee OA;
however, issues related to their appropriate dosage, patient comfort and
compliance remain as substantial challenges to long-term use. Identi-
ﬁed gaps in the literature include optimal dosage, characteristics of
those who respond best, effects on disease progression, and economic
evaluations.
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Purpose: To introduce a nationwide initiative in Denmark (Good Life
with Arthritis in Denmark (GLA:D)) aimed at implementing interna-
tional guidelines for knee and hip osteoarthritis (OA) and evaluate the
short-term and long-term effectiveness of a pilot study.
